5th World Congress on Cancer Therapy
The Research Institute at Nationwide Children’s Hospital, USA
Title: Alterations in actin binding proteins and miR~17-92 cluster in cancer cell metastasis and attenuation by DHA
Biography: Mehboob Ali
The talk will cover ourcurrent investigationsfocused on characterizing actin binding proteins and their roles in the context of cancer cell metastasis and cell death. Recently, we demonstrated that the actin binding protein VASP, was diff erentially phosphorylated at S157 and S239 and this phosphorylation was associated with proliferation and invasive phenotypes. Furthnore, we have identifi ed interactions between the actin binding proteins profi lin1 and pVASP S157 as well as cofi lin1 and pVASP 239. Th ese interactions are associated with altered subcellular distribution, specifi cally nuclear localization. Interestingly, miR- 17~92 has been shown to be elevated in cancer models and we also observed elevations in our models. Profi lin and cofi lin are predicted targets of the miR-17~92 components which implies a possible link between changes in profi lin and cofi linexpression and miR-17~92. Moreover, docosahexaenoic acid (DHA), a polyunsaturated fatty acid and dietary supplementis currently being investigated as a new and novel concept based therapy for cancer control. In our models, DHA supplementation was able tomodifying expression and subcellular distribution of actin binding proteins as well as decrease expression of the miR- 17~92 cluster. Our data identify novel, new modifi cations in actin binding protein expression and associations with miR-17~92 cluster that are attenuated by DHA supplementation. Collectively, these data indicate a therapeutic potential for DHA in modulatingin cancer cell survival and metastasis.